# EDGAR Filing Document

**Accession Number:** 0001599298
**File Stem:** 0000000000-23-000359
**Filing Date:** 2023-1
**Character Count:** 9946
**Document Hash:** f77fb850e30da277e69c5672b982e272
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-000359.hdr.sgml**: 20230306

**ACCESSION NUMBER**: 0000000000-23-000359

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230112

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Summit Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001599298
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 2882 SAND HILL ROAD
- **STREET 2:** SUITE 106
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** 617-514-7149

**MAIL ADDRESS:**
- **STREET 1:** 2882 SAND HILL ROAD
- **STREET 2:** SUITE 106
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Summit Therapeutics plc
- **DATE OF NAME CHANGE:** 20150219

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Summit Corp plc
- **DATE OF NAME CHANGE:** 20140205

## Text-Extract

```

United States securities and exchange commission logo

                               January 12, 2023

       Robert Duggan
       Chairman and Chief Executive Officer
       Summit Therapeutics Inc.
       2882 Sand Hill Road, Suite 106
       Menlo Park, CA 94025

                                                        Re: Summit Therapeutics
Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed December 21,
2022
                                                            File No. 333-268932

       Dear Robert Duggan:

              We have limited our review of your registration statement to
those issues we have
       addressed in our comments. In some of our comments, we may ask you to
provide us with
       information so we may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-3

       Subscription Price, page 40

   1.                                                   Please revise to
explain why the Board formed a Special Committee and identify the
                                                        members of that
committee.
   2.                                                   We note your disclosure
that in determining the Subscription Price the Special Committee
                                                        considered the average
price for the 30-day period prior to the filing of the preliminary
                                                        proxy statement on
November 29, 2022. With a view to disclosure and with reference to
                                                        your risk factor
disclosure at the top of page 31, please tell what consideration, if any, the
                                                        Special Committee or
Board has given or will give to revising the Initial Price to reflect
                                                        more recent market
trading. In this regard, we note that the stock price increased
                                                        significantly beginning
in early December. To the extent that the Initial Price will be set at
                                                        a significant discount
to the current market price, please revise the cover page to highlight
 Robert Duggan
Summit Therapeutics Inc.
January 12, 2023
Page 2
      the size of the discount and the attendant risks to shareholders.
3.    With a view to disclosure and with reference to the second risk factor
disclosures on pages
      31 and 32, please tell us what consideration the Board gave to including
a floor price for
      the offer and why it decided to include the Alternate Price feature.
Also, discuss what
      consideration, if any, given to making subscriptions revocable in the
event that the stock
      price materially decreases during the offering period. Similarly tell us
what steps you
      would take if the Board were to determine during the pendency of the
offering to conduct
      a reverse stock split either during or immediately following the
offering.
4.    We note your statement on the cover page that to the extent the Alternate
Price is lower
      than the Initial Price, you will sell additional shares of common stock.
Please also revise
      your disclosure to discuss your plans if the Alternate Price were to
decline such that the
      number of shares of common stock to be offered would cause you to exceed
the number
      of authorized shares of common stock set forth in your certificate of
incorporation.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Alan Campbell at (202) 551-4224 or Joe McCann at (202)
551-6262
with any questions.

                                                             Sincerely,
FirstName LastNameRobert Duggan
                                                             Division of
Corporation Finance
Comapany NameSummit Therapeutics Inc.
                                                             Office of Life
Sciences
January 12, 2023 Page 2
cc:       Adam Finerman, Esq.
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

January 12, 2023

Robert Duggan
Chairman and Chief Executive Officer
Summit Therapeutics Inc.
2882 Sand Hill Road, Suite 106
Menlo Park, CA 94025

**Re: Summit Therapeutics Inc.**
**Registration Statement on Form S-3**
**Filed December 21, 2022**
**File No. 333-268932**

Dear Robert Duggan:

We have limited our review of your registration statement to those issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Registration Statement on Form S-3

Subscription Price, page 40

1. Please revise to explain why the Board formed a Special Committee and identify the members of that committee.
2. We note your disclosure that in determining the Subscription Price the Special Committee considered the average price for the 30-day period prior to the filing of the preliminary proxy statement on November 29, 2022. With a view to disclosure and with reference to your risk factor disclosure at the top of page 31, please tell what consideration, if any, the Special Committee or Board has given or will give to revising the Initial Price to reflect more recent market trading. In this regard, we note that the stock price increased significantly beginning in early December. To the extent that the Initial Price will be set at a significant discount to the current market price, please revise the cover page to highlight

Robert Duggan
Summit Therapeutics Inc.
January 12, 2023
Page 2

the size of the discount and the attendant risks to shareholders.

3. With a view to disclosure and with reference to the second risk factor disclosures on pages 31 and 32, please tell us what consideration the Board gave to including a floor price for the offer and why it decided to include the Alternate Price feature. Also, discuss what consideration, if any, given to making subscriptions revocable in the event that the stock price materially decreases during the offering period. Similarly tell us what steps you would take if the Board were to determine during the pendency of the offering to conduct a reverse stock split either during or immediately following the offering.

4. We note your statement on the cover page that to the extent the Alternate Price is lower than the Initial Price, you will sell additional shares of common stock. Please also revise your disclosure to discuss your plans if the Alternate Price were to decline such that the number of shares of common stock to be offered would cause you to exceed the number of authorized shares of common stock set forth in your certificate of incorporation.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

You may contact Alan Campbell at (202) 551-4224 or Joe McCann at (202) 551-6262 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Adam Finerman, Esq.